Drug intelligence / Profile preview

CP216

Development stage: Preclinical
Lead developer: Consegna Pharma
Modality: Small Molecules
Administration: Intramuscular, Subcutaneous

Overview

CP216 is a long-acting injectable (LAI) formulation of naloxone, a small molecule opioid antagonist, developed by Consegna Pharma. It is designed to provide sustained release of naloxone over a 12 to 24-hour period to reverse or prevent opioid-induced respiratory depression. The drug acts as a competitive antagonist primarily at the mu-opioid receptor (MOR). CP216 is being developed via the FDA's 505(b)(2) regulatory pathway, which allows for the approval of new formulations of previously approved drugs. It is currently in the preclinical stage for the treatment of opioid abuse and overdose reversal.

Other names: naloxone long-acting injectable

Targets

KOR (Kappa opioid receptor)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)

Beyond the preview

Go deeper on CP216.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CP216.

Explore the full profile